Table 9 Characteristics of patients according to the expression level of ERCC2
From: Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Characteristics | High expression (n = 48 | Low expression (n = 45) | P-value |
|---|---|---|---|
Age, years | 53.15 ± 1.915 | 54.91 ± 2.049 | 0.53 |
Male sex | 25 | 23 | 0.93 |
Pre-bevacizumab KPS score | 60.68 ± 2.262 | 56.36 ± 2.207 | 0.18 |
Molecular type | |||
 IDH wild type | 34 | 43 |  < 0.05 |
 MGMT promoter status (methylated/unmethylated/NA) | 13/3/22 | 20/8/17 |  |
Surgical resection type | |||
 Partial resection | 21 | 17 | 0.56 |
 Gross total resection | 27 | 28 |  |
Drug treatment | |||
 Temozolomide + bevacizumab | 29 | 29 | 0.68 |
 Monotherapy | 19 | 16 |  |
 Temozolomide duration, days | 268 ± 30.71 | 176.1 ± 18.51 | 0.03 |
 .Avastin dose, mg/kg | 610.7 ± 18.31 | 571.6 ± 17.44 | 0.13 |
Treatment outcomes | |||
 Overall survival, days | 1082 ± 121.4 | 619.2 ± 58.07 | 0.001 |
 Progression-free survival, days | 588.2 ± 90.81 | 289.4 ± 33.99 | 0.003 |
 Initial tumor size, mm3 | 43443 ± 5978 | 39304 ± 4679 | 0.59 |
 Recurred tumor size, mm3 | 28949 ± 5759 | 33476 ± 5389 | 0.57 |